Bio-Techne (TECH) Competitors

Bruker (NASDAQ:BRKR) and Bio-Techne (NASDAQ:TECH) are both mid-cap life sciences tools & services companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Do analysts recommend BRKR or TECH?

Bruker presently has a consensus price target of $51.30, indicating a potential upside of 54.19%. Bio-Techne has a consensus price target of $70.42, indicating a potential upside of 32.89%. Given Bruker's higher possible upside, research analysts plainly believe Bruker is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	0 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.45
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.77

Is BRKR or TECH a better dividend stock?

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.6%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Bruker pays out 38.5% of its earnings in the form of a dividend. Bio-Techne pays out 69.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Does the media refer more to BRKR or TECH?

In the previous week, Bio-Techne had 3 more articles in the media than Bruker. MarketBeat recorded 12 mentions for Bio-Techne and 9 mentions for Bruker. Bio-Techne's average media sentiment score of 1.08 beat Bruker's score of 0.96 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of BRKR or TECH?

79.5% of Bruker shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 27.3% of Bruker shares are owned by company insiders. Comparatively, 3.9% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has better valuation & earnings, BRKR or TECH?

Bruker has higher revenue and earnings than Bio-Techne. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.37B	1.50	$113.10M	$0.52	63.98
Bio-Techne	$1.22B	6.81	$73.40M	$0.46	115.20

Is BRKR or TECH more profitable?

Bio-Techne has a net margin of 6.02% compared to Bruker's net margin of 2.31%. Bruker's return on equity of 17.89% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	2.31%	17.89%	5.38%
Bio-Techne	6.02%	13.43%	10.32%

Which has more volatility & risk, BRKR or TECH?

Bruker has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Summary

Bio-Techne beats Bruker on 12 of the 19 factors compared between the two stocks.